News
ADAG
2.390
+1.70%
0.040
Weekly Report: what happened at ADAG last week (0415-0419)?
Weekly Report · 4d ago
Weekly Report: what happened at ADAG last week (0408-0412)?
Weekly Report · 04/15 11:47
Weekly Report: what happened at ADAG last week (0401-0405)?
Weekly Report · 04/08 11:53
Analysts Offer Insights on Healthcare Companies: eFFECTOR Therapeutics (EFTR), Adagene (ADAG) and Aquestive Therapeutics (AQST)
TipRanks · 04/05 10:30
12 Health Care Stocks Moving In Monday's Intraday Session
Sunshine Biopharma (NASDAQ:SBFM) stock rose 86.3% to $0.11 during Monday's regular session. Xilio Therapeutics stock rose 25.93% and Mesoblast shares moved upwards by 20.95%. Eiger BioPharmaceuticals stock fell 67.8% during the regular session to $1.61.
Benzinga · 04/01 16:31
Weekly Report: what happened at ADAG last week (0325-0329)?
Weekly Report · 04/01 11:50
Adagene Inc. Strikes Deal to Sell Depositary Shares
Adagene, Inc. Has entered into a sales agreement with Leerink Partners LLC to sell American Depositary Shares. The move allows Adagene to potentially raise capital flexibly, depending on market conditions and their operational needs. The company will sell 1.25 ordinary shares in May 2022.
TipRanks · 03/29 19:57
Adagene ADR Non-GAAP EPS of -$0.21, revenue of $18.11M
Seeking Alpha · 03/29 16:47
Adagene’s Breakthroughs Promise Future Growth
Adagene, Inc.’s 2023 financial report reveals a successful year with a cash balance that supports operations into 2026. Their lead product, ADG126, has shown promising results in treating metastatic colorectal cancer. The company's SAFEbody platform is expected to drive progress in cancer therapies.
TipRanks · 03/29 13:57
Adagene Reports Full Year 2023 Financial Results and Provides Corporate Update
Barchart · 03/29 08:00
Weekly Report: what happened at ADAG last week (0318-0322)?
Weekly Report · 03/25 11:53
Weekly Report: what happened at ADAG last week (0311-0315)?
Weekly Report · 03/18 11:51
Weekly Report: what happened at ADAG last week (0304-0308)?
Weekly Report · 03/11 11:47
Weekly Report: what happened at ADAG last week (0226-0301)?
Weekly Report · 03/04 11:50
Weekly Report: what happened at ADAG last week (0219-0223)?
Weekly Report · 02/26 12:07
Weekly Report: what happened at ADAG last week (0212-0216)?
Weekly Report · 02/19 12:09
Weekly Report: what happened at ADAG last week (0205-0209)?
Weekly Report · 02/12 11:56
Health Care Sector Update for 02/09/2024: SYBX, MRNA, ADAG, HUMA
NASDAQ · 02/09 20:54
Adagene Announced Progress, Expansion Of The Clinical Collaboration Development Program For Its Masked, Anti-CTLA-4 SAFEbody, ADG126 In Combination With Merck's Keytruda (Pembrolizumab), In Patients With Metastatic Microsatellite-stable Colorectal Cancer
Interim data from additional MSS CRC patients dosed at 10 mg/kg in combination with pembrolizumab anticipated in 2024 at a medical conference. Received clearance from China's Center for Drug Evaluation to evaluate ADG126 in combination to explore enhanced efficacy.
Benzinga · 02/09 11:03
Adagene Announces Progress and Expansion of Clinical Collaboration Program for Masked, Anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with KEYTRUDA® (pembrolizumab) to Demonstrate Further Efficacy in Patients with Metastatic
Barchart · 02/09 05:00
More
Webull provides a variety of real-time ADAG stock news. You can receive the latest news about Adagene Inc. through multiple platforms. This information may help you make smarter investment decisions.
About ADAG
Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. The Company is principally engaged in the research, development and production of monoclonal antibody drugs for cancers. The Company’s main products include: ADG106 is being developed for the treatment of advanced solid tumors and non-Hodgkin's lymphoma, or NHL. ADG126 is designed to address the toxicity and efficacy issues related to the MOA of existing approved CTLA-4 immuno-oncology therapies and to expand the potential of CTLA-4 as a target for the treatment of cancer. ADG116 is designed to target a unique conserved epitope of CTLA-4. And ADG104, a monospecific antibody that targets PD-L1 and is in Phase Ib and Phase II clinical trials concurrently in China.